Femasys Inc. FEMY

Femasys Inc. advances OB/GYN expansion as Minnesota Women’s Care adopts the FemaSeed fertility portfolio. Single clinic adoption signals moderate progress in Femasys product market penetration.

Femasys Inc. partners with CapexMD to expand patient access to FemaSeed fertility portfolio. Partnership broadens access to core fertility product with moderate revenue upside.

Femasys Inc. partners with UNC Health to introduce its FemaSeed fertility portfolio across statewide OB/GYN care locations in North Carolina. Statewide partnership expands FemaSeed availability and accelerates commercial adoption across multiple sites.

Femasys Inc. secures FDA pathway for non-surgical contraceptive. FDA pathway clearance advances Femasys core product toward commercialization and revenue.

FEMY stock rallies after securing a key regulatory milestone for its investigational birth control technology, with retail investors projecting 500% upside potential. Regulatory milestone advances Femasys core birth control product and lifts stock with major upside forecasts.

Femasys secures FDA approval for modular PMA pathway for FemBloc. FDA approval advances FemBloc toward commercialization and boosts company trajectory.

Femasys secures FDA approval for modular PMA submission approach for FemBloc. FDA approval of modular PMA approach accelerates FemBloc path to potential market approval and revenue.

Femasys Inc. reported financial results for the quarter ended June 30, 2026 and issued a corporate update. Quarterly financial results and corporate updates typically affect short-term market sentiment and investor views without fundamentally altering long-term company trajectory.

Femasys secures first issued blended polymer patents, strengthening and extending global patent protection for FemBloc®. Extended patent protection for FemBloc bolsters Femasys competitive position in medical devices.

Femasys Inc. secures $30 million private placement financing with potential total proceeds reaching $90 million. Large capital infusion directly bolsters Femasys balance sheet and funds ongoing development initiatives.

Femasys Inc. (FEMY) received CE Mark approval for its FemHSG™ Catheter, expanding its fertility care portfolio in Europe. CE Mark approval enables commercialization of FemHSG™ Catheter in Europe, driving international revenue growth and market expansion for Femasys.

Femasys Inc. (FEMY) announced financial results for the quarter ended March 31, 2026, and provided a corporate update. Quarterly financial results and corporate update affect key financial performance and investor sentiment.

Femasys Inc. achieves initial commercial use of FemaSeed® Complete, enabling OB/GYNs to deliver first-line fertility treatment. Initial commercial use of FemaSeed® Complete signifies a major product launch milestone that could drive revenue and strengthen FEMY's position in the fertility market.

Femasys Inc. (FEMY) launches FemaSeed® Complete, a new product for OB/GYNs, at the ACOG 2026 conference. Launching FemaSeed® Complete at ACOG 2026 targets key OB/GYN market, driving significant revenue growth and competitive positioning.

Femasys Inc. (FEMY) enters the Israeli market with its fertility portfolio to accelerate international growth. Israeli market entry expands Femasys's fertility portfolio reach, signaling major strategic growth with potential for revenue uplift and improved market positioning.

Femasys Inc. (FEMY) appointed John Canning as Chief Operating Officer to drive operational execution and advance commercial growth. Appointing a seasoned COO focuses on operational efficiency and commercial acceleration, moderately enhancing FEMY's trajectory.

Femasys Inc. (FEMY) announced financial results for the year ended December 31, 2025, and provided a corporate update. Annual financial results disclosure and corporate update represent major events that significantly affect investor sentiment and company trajectory.

Femasys Inc. (FEMY) initiated patient enrollment in the pivotal clinical trial for FemBloc, advancing the permanent contraception device toward U.S. FDA approval. Initiating pivotal trial enrollment for FemBloc marks a critical regulatory milestone that could significantly enhance FEMY's product pipeline and market valuation.

Femasys Inc. announces FemBloc® Permanent Birth Control has achieved MDSAP Certification, advancing global market access. MDSAP Certification for FemBloc® facilitates regulatory approvals and commercialization in multiple countries, significantly enhancing Femasys' international expansion and revenue potential.

Femasys Inc. (FEMY) received AMA CPT Editorial Panel approval for a new Category III CPT code for FemaSeed Intratubal Insemination, facilitating reimbursement and broader adoption by healthcare providers. CPT code approval enables reimbursement for FemaSeed, significantly enhancing commercialization potential and revenue growth for Femasys.

Femasys Inc. has partnered with a Swiss company to expand its commercial presence in Europe for its FemBloc, FemaSeed, and other portfolio products. This collaboration aims to enhance market access and distribution capabilities in the region, potentially increasing the company's footprint and sales in the European market. The partnership represents a significant strategic move that could enhance Femasys's market position and investor sentiment in Europe.

Femasys Inc. has received a 180-day extension from Nasdaq to comply with the minimum bid price requirement. The extension allows the company until May 2024 to achieve a closing bid price of at least $1.00 per share for 10 consecutive trading days. This extension is crucial for Femasys to maintain its listing on the Nasdaq stock exchange. The extension provides Femasys with additional time to meet compliance requirements, which may positively influence investor sentiment and stock performance.

Femasys Inc. has partnered with Refuah Health Center to enhance access to its FemaSeed® product in community-based healthcare settings. This collaboration aims to improve first-line treatment options for patients, expanding the reach of FemaSeed® and promoting its use in underserved areas. The partnership is expected to facilitate better patient outcomes and increase the product's visibility in the market. The partnership is a significant strategic move that could enhance market penetration and improve financial performance.

Femasys Inc. has received U.S. FDA clearance for its next-generation FemVue diagnostic device, which is designed to enhance the evaluation of the female reproductive system. This advancement is expected to improve the accuracy and efficiency of diagnostic procedures in gynecology, potentially expanding the company's market presence and product offerings. FDA clearance for a next-generation diagnostic device is a significant regulatory milestone that can enhance product offerings and market competitiveness.

PharmaCyte Biotech has successfully monetized its stake in Femasys Inc., enhancing its cash position. This strategic capital deployment underscores PharmaCyte's focus on strengthening its financial resources. The monetization of the stake may provide Femasys with additional financial flexibility, impacting its operations and market sentiment moderately.

Femasys Inc. reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational developments. The company continues to focus on expanding its product offerings and market presence, aiming to enhance shareholder value. Management provided insights into future strategies and anticipated challenges in the evolving healthcare landscape. Moderate revenue growth and strategic developments may influence Femasys's competitive positioning and financial performance.

Femasys Inc. has secured a second partner order for its FemBloc® product in Europe, marking a significant step in its global growth strategy. This order follows the initial partnership and highlights the increasing demand for FemBloc® in the European market, which is expected to enhance the company's market presence and revenue potential. The second partner order for FemBloc® indicates a significant strategic move that could enhance Femasys's market position and financial performance.

Femasys Inc. has received FDA approval to advance to the final phase of its FemBloc® trial, a significant step for the company. Additionally, Femasys has secured $12 million in financing, with the potential to reach $58 million. This funding will support the trial and further development of its product. FDA approval and substantial financing are likely to significantly impact Femasys's future performance and market position.

Femasys Inc. has announced the initiation of a post-market surveillance study for its FemBloc® permanent birth control product in Europe. This study aims to gather additional data on the product's safety and effectiveness following its market introduction. The initiation of a post-market surveillance study may moderately influence Femasys's market position and investor sentiment regarding FemBloc®.

Femasys Inc. will exhibit at the ASRM 2025 Scientific Congress & Expo, showcasing its innovative products and solutions in reproductive health. The event is a significant platform for the company to engage with healthcare professionals and highlight advancements in its offerings. Participation in such a prominent congress underscores Femasys's commitment to addressing women's health needs and expanding its market presence. Participation in a major scientific congress can enhance visibility and networking opportunities, potentially influencing product adoption and market sentiment.